Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

Chow, 2008, Contemporary renal cell cancer epidemiology, Cancer J, 14, 288, 10.1097/PPO.0b013e3181867628 Choueiri, 2017, Systemic therapy for metastatic renal-cell carcinoma, N Engl J Med, 376, 354, 10.1056/NEJMra1601333 Flanigan, 2004, Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis, J Urol, 171, 1071, 10.1097/01.ju.0000110610.61545.ae Choueiri, 2011, The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy, J Urol, 185, 60, 10.1016/j.juro.2010.09.012 Heng, 2014, Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium, Eur Urol, 66, 704, 10.1016/j.eururo.2014.05.034 Méjean, 2018, Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma, N Engl J Med, 379, 417, 10.1056/NEJMoa1803675 Linehan, 2016, Comprehensive molecular characterization of papillary renal-cell carcinoma, N Engl J Med, 374, 135, 10.1056/NEJMoa1505917 Heng, 2009, Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study, J Clin Oncol, 27, 5794, 10.1200/JCO.2008.21.4809 Wells, 2017, Characterizing the outcomes of metastatic papillary renal cell carcinoma, Cancer Med, 6, 902, 10.1002/cam4.1048 Hanna, 2016, Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study, J Clin Oncol, 34, 3267, 10.1200/JCO.2016.66.7931 Marchioni, 2017, Survival after cytoreduc-tive 363 nephrectomy in metastatic non-clear cell renal cell carcinomapatients: 364 a population-based study, Eur Urol Focus Aizer, 2014, Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC), BJU Int, 113, E67, 10.1111/bju.12442 Ravaud, 2015, First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG), Ann Oncol, 26, 1123, 10.1093/annonc/mdv149 Motzer, 2018, Cytoreductive nephrectomy—patient selection is key, N Engl J Med, 379, 481, 10.1056/NEJMe1806331 Bex, 2017, Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME), Ann Oncol, 28, mdx440.030 Bex, 2019, Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial, JAMA Oncol, 5, 164, 10.1001/jamaoncol.2018.5543